Exhibit 99.1

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED

SEPTEMBER 30, 2021

(UNAUDITED)

 

1

 

 

INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021

(UNAUDITED)

 

Item

 

Page

Consolidated Balance Sheets

 

2

Consolidated Statements of Operations and Comprehensive Loss

 

3

Consolidated Statements of Changes in Equity

 

4-5

Consolidated Statements of Cash Flows

 

6

Notes to Condensed Consolidated Interim Financial Statements

 

7-18

1

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

Consolidated Balance Sheets      
(in thousands, except share data)      
   September 30, 2021   December 31, 2020 
       
ASSETS      
Current assets      
Cash and cash equivalents $332,871  $272,092 
Short-term deposits  187,000   27,000 
Accounts receivable, net of allowance for credit losses of $0.7 million and $0.9 million as of September 30, 2021 and December 31, 2020  121,848   106,068 
Inventories  119,925   131,672 
Prepaid expenses  8,634   6,717 
Other current assets  27,317   16,943 
Total current assets  797,595   560,492 
Non-current assets      
Property, plant and equipment, net  199,668   201,232 
Goodwill  39,750   35,694 
Other intangible assets, net  117,010   131,569 
Operating lease right-of-use assets  15,624   21,298 
Other non-current assets  58,365   39,717 
Total non-current assets  430,417   429,510 
Total assets $1,228,012  $990,002 
      
LIABILITIES AND EQUITY      
Current liabilities      
Accounts payable  $48,292  $16,987 
Accrued expenses and other current liabilities  30,875   31,061 
Accrued compensation and related benefits   36,983   25,659 
Deferred revenues - short term  49,104   49,165 
Operating lease liabilities - short term  7,514   9,282 
Total current liabilities  172,768   132,154 
Non-current liabilities      
Deferred revenues - long term  17,980   14,227 
Operating lease liabilities - long term  8,353   12,567 
Contingent consideration  40,589   37,400 
Other non-current liabilities  37,869   34,059 
Total non-current liabilities  104,791   98,253 
Total liabilities $277,559  $230,407 
      
Contingencies (see note 12)  
   
 
      
Redeemable non-controlling interests  -   227 
      
Equity      
Ordinary shares, NIS 0.01 nominal value, authorized 180,000 thousand shares; 65,467 thousand shares and 56,617 thousand shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively  182   155 
Additional paid-in capital  3,001,685   2,753,955 
Accumulated other comprehensive loss  (8,372  (8,846
Accumulated deficit  (2,043,042  (1,985,896
Total equity  950,453   759,368 
Total liabilities and equity $1,228,012  $990,002 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

2

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

Consolidated Statements of Operations and Comprehensive Loss               
                
 Three Months Ended September 30, Nine Months Ended September 30,
in thousands, except per share data 2021   2020   2021   2020 
                
Revenues               
Products$108,888  $83,548  $299,517  $240,597 
Services 50,121   44,344   140,686   137,825 
  159,009   127,892   440,203   378,422 
Cost of revenues               
Products 54,820   47,339   151,471   126,556 
Services 36,001   30,784   101,697   98,491 
  90,821   78,123   253,168   225,047 
                
Gross profit 68,188   49,769   187,035   153,375 
                
Operating expenses               
Research and development, net 22,645   19,562   65,683   65,059 
Selling, general and administrative 67,462   48,343   184,353   155,630 
Goodwill impairment 
-
       386,154   
-
   386,154 
  90,107   454,059   250,036   606,843 
                
Operating loss (21,919)  (404,290)  (63,001  (453,468)
                
Financial expenses, net (634)  (167)  (1,383  (847)
                
Loss before income taxes (22,553)  (404,457)  (64,384  (454,315)
Income tax benefit 699   343   6,009   2,250 
                
Share in profit (loss) of associated companies 3,778   (952)  1,229   (2,740)
                
Net loss$(18,076) $(405,066) $(57,146 $(454,805)
                
Net loss attributable to non-controlling interests 
-
   (4)  
-
   (54)
                
Net loss attributable to Stratasys Ltd.$(18,076) $(405,062) $(57,146 $(454,751)
                
Net loss per ordinary share attributable to Stratasys Ltd. - basic and diluted$(0.28) $(7.35) $(0.91 $(8.29)
                
Weighted average ordinary shares outstanding. - basic and diluted 65,018   55,086   62,888   54,851 
                
Comprehensive loss               
Net loss (18,076)  (405,066)  (57,146  (454,805)
Other comprehensive income (loss), net of tax:               
Foreign currency translation adjustments (2,247)  1,056   (2,105  (611)
Unrealized gains (losses) on derivatives designated as cash flow hedges 578   (1,851)  2,579   (962)
Other comprehensive income (loss), net of tax (1,669)  (795)  474   (1,573)
Comprehensive loss (19,745)  (405,861)  (56,672  (456,378)
              Less: comprehensive loss attributable to non-controlling interests 
-
   (4)  
-
   (54)
Comprehensive loss attributable to Stratasys Ltd.$(19,745) $(405,857) $(56,672 $(456,324)
                

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

3

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

Consolidated Statements of Changes in Equity      
(in thousands )            
Three and Nine Months Ended September 30, 2021 and 2020      
         Accumulated  
     Additional   Other  
 Ordinary SharesPaid-InAccumulated ComprehensiveTotal
 Number of shares Par ValueCapitaldeficitLossEquity
Balance as of December 31, 2020 56,617  155  2,753,955  (1,985,896 (8,846 759,368 
Issuance of shares in connection with stock-based compensation plans 670  2  2,881  
-
  
-
  2,883 
Stock-based compensation -  
-
  7,205  
-
  
-
  7,205 
Public offering of ordinary shares, net 7,931  24  218,851  
-
  
-
  218,875 
Deferred tax assets in connection with public offering expenses -  
-
  1,156   
-
   
-
  1,156 
Comprehensive income (loss) -  
-
  
-
  (18,911 1,212  (17,699
Balance as of March 31, 2021 65,218 $181 $2,984,048 $(2,004,807$(7,634$971,788 
Issuance of shares in connection with stock-based compensation plans 178  
*
  633  
-
  
-
  633 
Stock-based compensation -  
-
  7,977  
-
  
-
  7,977 
Deferred tax assets in connection with public offering expenses -  
-
  175  
-
  
-
  175 
Comprehensive income (loss) -  
-
  
-
  (20,159 931  (19,228
Balance as of June 30, 2021 65,396 $181 $2,992,833 $(2,024,966$(6,703$961,345 
Issuance of shares in connection with stock-based compensation plans 71  1  692  
-
  
-
  693 
Stock-based compensation -  
-
  7,958  
-
  
-
  7,958 
Expenses in connection with March 2021 public offering -  
-
  (25 
-
  
-
  (25
Reduction of redeemable non-controlling interest -  
-
  227  
-
  
-
  227 
Comprehensive loss -  
-
  
-
  (18,076 (1,669 (19,745
Balance as of September 30, 2021 65,467 $182 $3,001,685 $(2,043,042$(8,372$950,453 
 
 
 
4

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

Consolidated Statements of Changes in Equity                        
(in thousands )                        
Three and Nine Months Ended September 30, 2021 and 2020                        
                   Accumulated     
           Additional        Other     
  Ordinary Shares  Paid-In   Accumulated    Comprehensive   Total 
   Number of shares    Par Value   Capital   deficit   Loss   Equity 
Balance as of December 31, 2019  54,441   148   2,706,894   (1,542,175)  (7,716)  1,157,151 
Issuance of shares in connection with stock-based compensation plans  358   1   29   
-
   
-
   30 
Stock-based compensation  -   
-
   4,907   
-
   
-
   4,907 
Comprehensive loss  -   
-
   
-
   (21,703)  (1,132)  (22,835)
Balance as of March 31, 2020  54,799  149  2,711,830  (1,563,878) (8,848) 1,139,253 
Issuance of shares in connection with stock-based compensation plans  231   1   22   
-
   
-
   23 
Stock-based compensation  -   
-
   6,111   
-
   
-
   6,111 
Comprehensive income (loss)  -   
-
   
-
   (27,986)  354   (27,632)
Balance as of June 30, 2020  55,030  150  2,717,963  $(1,591,864)  (8,494) $1,117,755 
Issuance of shares in connection with stock-based compensation plans  82   
*
   
-
   
-
   
-
   
*
 
Stock-based compensation  -   
-
   4,876   
-
   
-
   4,876 
Comprehensive loss  -   
-
   
-
   (405,062)   (795)   (405,857) 
Balance as of September 30, 2020  55,112  150  2,722,839  (1,996,926)  (9,289)  716,774 

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

 

5

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

Consolidated Statements of Cash Flows     
   Nine Months Ended September 30,
in thousands   2021   2020 
      
Cash flows from operating activities     
Net loss  $(57,146 $(454,805
      
Adjustments to reconcile net loss to net cash provided by operating activities:     
Goodwill impairment   
-
   386,154 
Impairment of other long-lived assets   1,944   5,557 
Depreciation and amortization   41,412   37,428 
Stock-based compensation   23,140   15,894 
Foreign currency transaction loss   4,210   (2,565
Deferred income taxes   (9,054  (1,541
Share in loss (profit) of associated companies   (1,173  2,740 
Revaluation of investments   556   
-
 
Other non-cash items, net   364   37 
      
Change in cash attributable to changes in operating assets and liabilities:     
Accounts receivable, net   (17,023  29,563 
Inventories   8,271   15,167 
Other current assets and prepaid expenses   (11,911  5,805 
Other non-current assets   3,834   2,681 
Accounts payable   29,204   (17,579
Other current liabilities   14,047   (8,430
Deferred revenues   3,470   (8,070
Other non-current liabilities   (2,749  (3,932
Net cash provided by operating activities   31,396   4,104 
      
Cash flows from investing activities      
Cash paid for acquisitions, net of cash acquired   (6,669  
-
 
Purchase of property and equipment   (16,193  (19,912
Investments in short-term bank deposits   (249,000  (27,000
Investments in unconsolidated entities   (7,000  
-
 
Proceeds from maturity of short-term bank deposits   89,000   
-
 
Proceeds from sale of equity method investment   
-
   3,175 
Net proceeds from divestitures of subsidiaries and associated companies    
-
   1,000 
Purchase of intangible assets   (1,219  (1,598
Other investing activities   (85  89 
Net cash used in investing activities   (191,166  (44,246
      
Cash flows from financing activities      
Proceeds from public offering, net of issuance costs   218,850   
-
 
Proceeds from exercise of stock options   3,699   53 
Other financing activities   406   
-
 
Net cash provided by financing activities   222,955   53 
     
Effect of exchange rate changes on cash, cash equivalents and restricted cash   (2,413  (484
      
Net change in cash, cash equivalents and restricted cash   60,772   (40,573
Cash, cash equivalents and restricted cash, beginning of period   272,216   293,597 
      
Cash, cash equivalents and restricted cash, end of period  $332,988  $253,024 
      
Supplemental disclosures of cash flow information:      
Transfer of inventory to fixed assets   2,760   2,445 
Transfer of fixed assets to inventory   844   281 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

6

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 1. Business Description and Basis of Presentation

 

Stratasys Ltd. (collectively with its subsidiaries, the “Company” or “Stratasys”) is a global leader in connected, polymer-based 3D printing solutions, across the entire manufacturing value chain. The Company leverages its competitive advantages, which include a broad set of best-in-class 3D printing platforms, software, a materials and technology partner ecosystem, innovative leadership, and global GTM infrastructure, in order to position itself to capture share in a significant and growing global marketplace, with a focus on manufacturing. The Company’s approximately 1,600 granted and pending additive technology patents to date have been used to create models, prototypes, manufacturing tools, and production parts for a multitude of industries including aerospace, automotive, transportation, healthcare, consumer products, dental, medical, and education. Stratasys’ products and comprehensive solutions improve product quality, development time, cost, and time-to-market. The Company’s 3D ecosystem of solutions and expertise includes 3D printers, materials, software, expert services, and on-demand parts production.

The condensed consolidated interim financial information herein is unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in the opinion of management, necessary for a fair statement of results for the interim period. The condensed consolidated interim financial statements include the accounts of Stratasys Ltd. and its subsidiaries. All intercompany accounts and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated in consolidation.

The Company's financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), which requires the Company to make estimates based on assumptions about current and, for some estimates, future economic and market conditions which affect reported amounts and related disclosures in its financial statements. Although the Company current estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from the Company expectations, which could materially affect its results of operations and financial position.

In particular, a number of estimates have been and will continue to be affected by the ongoing COVID-19 pandemic. The severity, magnitude and duration of, and recovery from, as well as the economic consequences of, the COVID-19 pandemic, remain uncertain, rapidly changing and difficult to predict. As a result, the accounting estimates and assumptions may change over time in response to COVID-19. Such changes could have an additional impact on the Company’s long-lived asset and intangible asset valuation; inventory valuation; assessment of the annual effective tax rate; and the allowance for expected credit losses and bad debt.

The results of operations for the three and nine months ended September 30, 2021 are not indicative of results that could be expected for the entire fiscal year. Certain financial information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. The reader is referred to the audited consolidated financial statements and notes thereto for the year ended December 31, 2020, filed with the U.S. Securities and Exchange Commission (the “SEC”) as part of the Company’s Annual Report on Form 20-F for such year on March 1, 2021.

 

Note 2. New Accounting Pronouncements

 

Accounting Pronouncements Adopted in 2021

In December 2019, the FASB issued new guidance to simplify the accounting for income taxes by removing certain exceptions to the general principles and simplification of areas such as franchise taxes, step-up in tax basis goodwill, separate entity financial statements and interim recognition of enactment of tax laws or rate changes The guidance will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted this guidance effective January 1, 2021, with no material impact on its consolidated financial statements.

7

STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
 
Note 3. Certain Transactions
 
 Origin acquisition
 
 On December 31, 2020 (the “Origin transaction date”) the Company acquired 3D printing start-up Origin Laboratories Inc. (“Origin”) for an aggregate purchase price of $97.1 million (the “Origin transaction”), including cash and shares. The acquisition enables Stratasys to expand its leadership through innovation in the fast-growing mass production parts market with a next-generation photopolymer platform. Stratasys expects Origin’s proprietary Programmable PhotoPolymerization (P3) technology to be an important growth engine for the Company. The acquisition was aimed at fortifying the Company's leadership in polymers and production applications of 3D printing in industries such as dental, medical, tooling, and select industrial, defense, and consumer goods markets.
 
In exchange for 100% of the outstanding shares of Origin the Company issued 1,488 thousand ordinary shares, paid cash upon closing, and is obligated to pay additional payments (combination of cash and shares) subject to performance-based earn-outs over 3 years.
 
The Origin transaction is reflected in accordance with ASC Topic 805, “Business Combinations”, using the acquisition method of accounting with the Company as the acquirer.
 
The following table summarizes the fair value of the consideration transferred to Origin stockholders for the Origin transaction:
 
 
 U.S. $ in thousands
Cash payments$33,025
Issuance of ordinary shares to Origin stockholders  26,636 
Contingent consideration at estimated fair value 37,400 
Total consideration$97,061 
 
 
 The fair value of the ordinary shares issued was determined based on the closing market price of the Company’s ordinary shares on the Origin transaction date.
 
In accordance with ASC Topic 805, the estimated contingent consideration as of the Origin transaction date was included in the purchase price. The total contingent payments could reach to a maximum aggregate amount of up to $40 million. Approximately 50% of the payments shall be settled in cash, and 50% shall be settled through the issuance of ordinary shares. The estimated fair value of the contingent consideration is based on management’s assessment of whether, and at what level, the financial metrics will be achieved, and the present value factors associated with the timing of the payments. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the fair value of contingent consideration will be recorded in Consolidated Statements of Operations and Comprehensive Loss. Refer to note 9. 
 
An additional payment of $6 million, which is subject to the founders' retention over 3 years, will be recorded as compensation expense over the retention period. Compensation expenses for the three and nine months ended September 30, 2021 were approximately $1.1 million and $3.3 million respectively.
8

STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
 
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, based on the information that is available as of September 30, 2021. Thus, the measurements of fair value reflected are subject to changes and such changes could be significant. The preliminary allocation of the purchase price to assets acquired and liabilities assumed is as follows:
 
 
 Allocation of Purchase Price
 (U.S. $ in thousands)
Cash and cash equivalents$2,083 
Goodwill 38,094 
Intangible assets 71,120 
Other assets 3,493 
Total assets acquired 114,790 
  
Net deferred tax liabilities 14,007 
Other labilities 3,722 
Total liabilities assumed 17,729 
  
Net assets acquired$97,061 
 
The allocation of the purchase price to net assets acquired and liability assumed resulted in the recognition of an intangible asset related to developed technology of $71 million. This intangible asset has a useful-life of 10 years. The fair value estimate of the developed technology is determined using a variation of the income approach known as the “Multi-Period Excess Earnings Approach”. This valuation technique estimates the fair value of an asset based on market participants’ expectations of the cash flows an asset would generate over its remaining useful life. The net cash flows were discounted to present value.
 
Pro forma information giving effect to the acquisition has not been provided as the impact of the transaction for purposes of Stratasys' consolidation results of operations and financial condition would not be material.
 
  XAAR acquisition
 
 
On November 1, 2021, the Company acquired the remaining 55% share of XAAR 3D, for an aggregate purchase price of $33.8 million. The Company paid cash upon closing and it is obligated to make additional earn-out payments and royalties on products and services sales for up to 15 years.

 
  RPS acquisition
 
 On February 16, 2021 the Company acquired RP Support Limited (“RPS”), a provider of industrial stereolithography 3D printers and solutions. In exchange for 100% of the outstanding shares of RPS, the Company paid cash upon closing and it is obligated to make additional payments (in cash), subject to performance-based criteria, via earn-out payments over two years.
 
  Marketable equity investment
 
The Company recognized in the three and nine months ended September 30, 2021 losses of $2.0 million and $1.2 million respectively, for revaluation of an equity investment. In prior periods the investment was treated as a non-marketable equity investment without readily determinable fair value. The entity in which the Company invested became public during the first quarter and accordingly the investment is now treated as a marketable equity investment.
 
9

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 4. Revenues

Disaggregation of Revenues

The following table presents the Company’s revenues disaggregated by geographical region (based on the Company's customers' locations) and revenue type for the three and nine months ended September 30, 2021 and 2020:

 

 Three months ended September 30,Nine months ended September 30,
  2021  2020 2021 2020
 (U.S. $ in thousands)(U.S. $ in thousands)
Americas        
Products $65,610  $52,827 $172,961 $145,871 
Service 37,962   33,770  105,673  106,000 
Total Americas 103,572   86,597  278,634  251,871 
         
EMEA        
Products  26,896   17,245  75,223  53,735 
Service 7,165   6,003  20,279  17,348 
Total EMEA 34,061   23,248  95,502  71,083 
         
Asia Pacific        
Products  16,382   13,476  51,333  40,991 
Service 4,994   4,571  14,734  14,477 
Total Asia Pacific 21,376   18,047  66,067  55,468 
         
Total Revenues$159,009  $127,892 $440,203 $378,422 

The following table presents the Company’s revenues disaggregated based on the timing of revenue recognition (at a specific point in time or over the course of time) for the three and nine months ended September 30, 2021 and 2020:

 

  Three months ended September 30,Nine months ended September 30,
   2021  2020 2021 2020
  (U.S. $ in thousands)(U.S. $ in thousands)
Revenues recognized in point in time from:         
Products $108,888  $83,548 $299,517 $240,597 
Services  12,056   10,387  33,781  29,809 
Total revenues recognized in point in time  120,944   93,935  333,298  270,406 
          
          
Revenues recognized over time from:         
Services  38,065   33,957  106,905  108,016 
Total revenues recognized over time  38,065   33,957  106,905  108,016 
          
Total Revenues $159,009  $127,892 $440,203 $378,422 
10

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Contract Assets and Contract Liabilities

Contract assets are recorded when the Company's right to consideration is conditional on constraints other than the passage of time. The Company had no material contract assets as of September 30, 2021 and December 31, 2020.

Contract liabilities include advance payments and billings in excess of revenue recognized, which are primarily related to advanced billings for service type warranty. Contract liabilities are presented under deferred revenues. The Company's deferred revenues as of September 30, 2021 and December 31, 2020 were as follows:

 

  September 30, 2021December 31, 2020
   
  U.S. $ in thousands
     
Deferred revenue*  67,084   63,392 

*Includes $18 million and $14.2 million under long term deferred revenue in the Company's consolidated balance sheets as of September 30, 2021 and December 31, 2020, respectively.

Revenue recognized in 2021 that was included in deferred revenue balance as of December 31, 2020 was $9.7 million and $41.8 million for the three and nine months ended September 30, 2021.

Remaining Performance Obligations

Remaining Performance Obligations (RPO) represent contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of September 30, 2021, the total RPO amounted to $121.4 million. The Company expects to recognize $102.1 million of this RPO during the next 12 months, $10.8 million over the subsequent 12 months and the remaining $8.6 million thereafter.

Incremental Costs of Obtaining a Contract

Sales commissions earned mainly by the Company’s sales agents are considered incremental costs of obtaining a contract with a customer, as the Company expects the benefit of those commissions to be longer than one year. The majority of the sales commissions are not subject to capitalization, as the commission expense is recognized as the related revenue is recognized. Sales commissions for initial contracts related to the service type warranty are deferred and then amortized on a straight-line basis over the expected customer relationship period if the Company expects to recover those costs. Amortization expense is included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. As of September 30, 2021 and December 31, 2020, the deferred commissions amounted to $6.6 million and $5 million, respectively.

 

11

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 5. Inventories

Inventories consisted of the following:

 

  September 30, 2021 December 31, 2020
   
  U.S. $ in thousands
Finished goods $53,576  $61,297 
Work-in-process  3,734   3,163 
Raw materials  62,615   67,212 
 $119,925  $131,672 

 

Note 6. Goodwill and Other Intangible Assets

Goodwill

Changes in the carrying amount of the Company’s goodwill for the nine months ended September 30, 2021 were as follows:

 

  U.S. $ in thousands
   
Goodwill as of January 1, 2021* $35,694 
Goodwill acquired**   1,716  
Measurement period adjustments  2,400 
Foreign currency translation adjustments  (60
Goodwill as of September 30, 2021 $39,750 

*The goodwill was acquired as part of the Origin acquisition. See Note 3.

**The goodwill was acquired as part of the RPS acquisition. See Note 3.

 
   
During the third quarter of 2020, the Company noted that indicators of potential impairment existed which required an interim goodwill impairment analysis for Stratasys-Objet reporting unit. These indicators included longer and deeper than expected reduction in the business, refinement to the Company’s business focus into additional inorganic technologies and sustained decline in the Company’s market capitalization during the prior two quarters, in each case, primarily as a result of the COVID-19 impact on the global economy and the Company’s business.
 
As a result of the factors discussed above, the Company revisited its assumptions supporting the cash flow projections for its Stratasys-Objet reporting unit, including: (i) the expected duration and depth of revenue reduction and certain revenue growth assumptions; (ii) the associated operating profit margins; and (iii) the long term growth rate. In estimating the discounted cash flow, the Company used the following key assumptions: the Company expected it would take approximately two years to regain the loss of revenue and return to its pre COVID-19 activity levels considering the impact of both volume and price with a similar effect on profitability. Following such period, the Company expects to return to similar growth rates as estimated in prior valuations. The Company assumed a long term terminal growth rate of 2.5%, which is lower than the 3.1% used in prior valuations. In addition, changes in business focus due to introduction of new technologies was expected to lower the total revenues related to the Stratasys-Objet reporting unit. The resulting cash flow amounts were discounted using the same discount rate of 13.5%.
 
Based on the revised cash flow projections, the value of the reporting unit had decreased below its carrying value, and the Company recorded in the third quarter of 2020, a goodwill impairment charge of $386.2 million, the entire reporting unit’s goodwill.
12

STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
   

Other Intangible Assets

Other intangible assets consisted of the following:

 

  September 30, 2021 December 31, 2020
   Carrying Amount,      Net   Carrying Amount,   Net
    Net of   Accumulated   Book   Net of Accumulated Book
    Impairment    Amortization   Value   Impairment  Amortization Value
  U.S. $ in thousands
Developed technology $365,039 $(276,097 $88,942  $357,863  $(260,123 $97,740 
Patents  18,768  (9,594  9,174   17,699   (8,487  9,212 
Trademarks and trade names  26,056  (21,962  4,094   26,036   (21,114  4,922 
Customer relationships  100,802   (86,002  14,800   101,107   (81,413  19,694 
Capitalized software development costs  7,410   (7,410  
-
   7,410   (7,410  - 
  $518,075  $(401,065 $117,010  $510,115 $(378,547$131,568 

Amortization expenses relating to intangible assets for the three-month periods ended September 30, 2021 and 2020 were approximately $7.7 million and $6.2 million, respectively. Amortization expenses relating to intangible assets for the nine-month periods ended September 30, 2021 and 2020 were approximately $23.0 million and $18.6 million, respectively.

As of September 30, 2021, the estimated amortization expenses relating to intangible assets for each of the following future periods were as follows:

  Estimated
  amortization expense
  (U.S. $ in thousands)
Remaining 3 months of 2021 $8,213 
2022  30,765 
2023  16,166 
2024  12,251 
2025 and thereafter  49,615 
Total $117,010 
 

 

Note 7. Net Loss Per Share

 

The following table presents the numerator and denominator of the basic and diluted net loss per share computations for the three and nine months ended September 30, 2021 and 2020:

  Three Months Ended September 30,Nine Months Ended September 30,
   2021   2020  2021 2020
  In thousands, except per share amountsIn thousands, except per share amounts
Numerator:         
Net loss attributable to Stratasys Ltd. for basic and diluted net loss per share  (18,076  (405,062 (57,146 (454,751
    
Denominator:       
Weighted average shares - for basic and diluted net loss per share  65,018   55,086  62,888  54,851 
      
Net loss per share attributable to Stratasys Ltd.      
Basic and diluted $(0.28 $(7.35$(0.91$(8.29

The computation of diluted net loss per share excluded share awards of 5.0 million shares and 4.8 million shares for the three and nine months ended September 30, 2021 and 2020, respectively, because their inclusion would have had an anti-dilutive effect on the diluted net loss per share.

 

13

 
 

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

 Note 8. Income Taxes

        The Company had income tax benefit of $0.7 million for the three-month period ended September 30, 2021 compared to income tax benefit of $0.3 million for the three-month period ended September 30, 2020, and income tax benefit of $6.0 million for the nine-month period ended September 30, 2021 compared to income tax benefit of $2.3 million for the nine-month period ended September 30, 2020. The Company’s effective tax rate as of September 30, 2021 was primarily impacted by our transition during the second quarter of 2021 to the new Israeli tax regime of “Preferred Technology Enterprise”, under which the Company is subject to a 12% tax rate, as well as different geographic mixes of earnings and losses and a valuation allowance on losses of the Company's US subsidiaries.

 

 

Note 9. Fair Value Measurements

 

Financial instruments measured at fair value

The following table summarizes the Company’s financial assets and liabilities that are carried at fair value on a recurring basis, in its consolidated balance sheets:

 September 30, 2021 December 31, 2020
 Level 2 Level 3 Level 2 Level 3
 (U.S. $ in thousands)
Assets:       
Foreign exchange forward contracts not designated as hedging instruments$67   
-
  $56   
-
 
Foreign exchange forward contracts designated as hedging instruments 634   
-
   793   
-
 
        
Liabilities:       
Foreign exchange forward contracts not designated as hedging instruments (2  
-
   (1,098  
-
 
Foreign exchange forward contracts designated as hedging instruments 
-
   
-
   (1,584  
-
 
Contingent consideration 
-
   40,589   
-
   37,400 
 $699  $40,589  $(1,833 $37,400 

The Company’s foreign exchange forward contracts are classified as Level 2, as they are not actively traded and are valued using pricing models that use observable market inputs, including interest rate curves and both forward and spot prices for currencies (Level 2 inputs).

Contingent consideration represents liabilities recorded at fair value in connection with acquisitions, and thus represents a Level 3 measurement within the fair value hierarchy (refer to Note 3).

Other financial instruments consist mainly of cash and cash equivalents, short-term deposits, current and non-current assets, accounts payable and other current liabilities. The fair value of these financial instruments approximates their carrying values.

 

14

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 10. Derivative instruments and hedging activities

Since the Company conducts its operations globally, it is exposed to global market risks and to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign currency exchange rates. The Company enters into transactions involving foreign currency exchange derivative financial instruments. The Company manages its foreign currency exposures on a consolidated basis, which allows the Company to net exposures and take advantage of any natural hedging. The transactions are designed to manage the Company’s net exposure to foreign currency exchange rates and to reduce the volatility of earnings and cash flows associated with changes in foreign currency exchange rates. The Company does not enter into derivative transactions for trading purposes.

The Company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities and forecasted transactions denominated in the New Israeli Shekel (“NIS”), Euro, GBP, Korean Won, Chinese Yuan and the Japanese Yen. The gains and losses on the hedging instruments partially offset losses and gains on the hedged items. Financial markets and currency volatility may limit the Company’s ability to hedge these exposures. These contracts mature through December 2021.

The following table summarizes the consolidated balance sheets classification and fair values of the Company’s derivative instruments:

 

    Fair Value Notional Amount
    September 30, December 31, September 30, December 31,
  Balance sheet location 2021 2020 2021 2020
    U.S. $ in thousands
Assets derivatives -Foreign exchange contracts, not designated as hedging instruments Other current assets $67  $56  $43,389  $36,882 
Assets derivatives -Foreign exchange contracts, designated as cash flow hedge Other current assets  634   793   20,765   10,417 
Liability derivatives -Foreign exchange contracts, not designated as hedging instruments Accrued expenses and other current liabilities  (2  (1,098  847   37,999 
Liability derivatives -Foreign exchange contracts, designated as hedging instruments Accrued expenses and other current liabilities  
-
   (1,584  
-
   50,186 
    $699  $(1,833 $65,001  $135,484 

Foreign exchange contracts not designated as hedging instruments

As of September 30, 2021, the notional amounts of the Company’s outstanding exchange forward contracts, not designated as hedging instruments, were $44.2 million, and were used to reduce foreign currency exposures. With respect to such derivatives, gain of $0.9 million and loss of $3.2 million were recognized under financial income (expenses), net for the three-month periods ended September 30, 2021 and 2020, respectively. Such gains or losses partially offset the foreign currency revaluation changes of the balance sheet items. These foreign currencies revaluation changes are also recognized under financial income (expenses), net.

Cash Flow Hedging - Hedges of forecasted foreign currency payroll and other operating expenses

As of September 30, 2021, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of $6.4 million into NIS. The Company uses short-term cash flow hedge contracts to reduce its exposure to variability in expected future cash flows resulting mainly from payroll costs and other operating expenses denominated in NIS. The changes in fair value of those contracts are included in the Company’s accumulated other comprehensive loss.

 

Cash Flow Hedging - Hedges of forecasted foreign currency revenue

As of September 30, 2021, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of 12.0 million Euro into U.S. dollars. The Company transacts business in U.S. dollars and in various other currencies. The Company may use foreign exchange or forward contracts to hedge certain cash flow exposures resulting from changes in these foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities of up to twelve months. The Company enters into these foreign exchange contracts to hedge a portion of its forecasted foreign currency denominated revenue in the normal course of business and accordingly, they are not speculative in nature.

15

 STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 11. Equity

a. Stock-based compensation plans

Stock-based compensation expenses for equity-classified stock options, restricted share units (“RSUs”) and performance-based restricted share units (PSUs) were allocated as follows:

 

  Three Months EndedNine Months Ended
  September 30,September 30,
  2021 2020 2021 2020
  U.S $ in thousandsU.S $ in thousands
        
Cost of revenues $805  $524 $2,227 $1,370 
Research and development, net  1,764   1,587  5,058  3,764 
Selling, general and administrative  5,389   2,765  15,855  10,623 
Total stock-based compensation expenses $7,958  $4,876 $23,140 $15,757 

A summary of the Company’s stock option activity for the nine months ended September 30, 2021 is as follows:

 

  Number of OptionsWeighted Average Exercise Price
Options outstanding as of January 1, 2021  2,102,529 $28.06 
Granted  46,366  3.15 
Exercised  (209,819 20.05 
Forfeited  (40,548 41.82 
Options outstanding as of September 30, 2021  1,898,528  28.04 
Options exercisable as of September 30, 2021  1,569,587 $30.66 

As of September 30, 2021, the unrecognized compensation cost of $2.5 million related to all unvested, equity-classified stock options is expected to be recognized as an expense over a weighted-average period of 3.2 years.

 

16

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

A summary of the Company’s RSUs and PSUs activity for the three months ended September 30, 2021 is as follows:

 

  Number of RSUs and PSUsWeighted Average Grant Date Fair Value
Unvested as of January 1, 2021  2,801,116 $21.08 
Granted  1,272,386  33.91 
Vested  (709,434 21.88 
Forfeited  (284,276 21.98 
Unvested as of September 30, 2021  3,079,792 $26.11 

The fair value of RSUs and PSUs is determined based on the quoted price of the Company’s ordinary shares on the date of the grant.

As of September 30, 2021, the unrecognized compensation cost of $60 million related to all unvested, equity-classified RSUs and PSUs is expected to be recognized as expense over a weighted-average period of 2.34 years.

 

b. Accumulated other comprehensive loss

The following tables present the changes in the components of accumulated other comprehensive income (loss), net of taxes, for the nine months ended September 30, 2021 and 2020, respectively:

 

  Nine Months Ended September 30, 2021
  Net Unrealized Gain (Loss) on Cash Flow Hedges  Foreign Currency Translation Adjustments  Total
  U.S. $ in thousands
         
Balance as of January 1, 2021 $(1,673  $(7,173  $(8,846
Other comprehensive income before reclassifications  2,427    (2,105   322 
Amounts reclassified from accumulated other comprehensive loss  152    
-
    152 
Other comprehensive income  2,579    (2,105   474 
Balance as of September 30, 2021 $906   $(9,278  $(8,372

 

17

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

  Nine Months Ended September 30, 2020
  Net Unrealized Gain (Loss) on Cash Flow Hedges  Foreign Currency Translation Adjustments  Total
  U.S. $ in thousands
         
Balance as of January 1, 2020 $(10  $(7,706  $(7,716
Other comprehensive income (loss) before reclassifications  (299   (611   (910
Amounts reclassified from accumulated other comprehensive loss  (663   
-
    (663
Other comprehensive income (loss)  (962   (611   (1,573
Balance as of September 30, 2020 $(972  $(8,317  $(9,289

 

c. Public offering of ordinary shares

During March 2021, the Company completed a public offering of $218.9 million, net of underwriting discounts and offering expenses. The total number of shares sold by the Company in the public offering was 7,931,034.
 
       A deferred tax asset in an amount of $1.3 million was recorded in respect of a tax benefit, arising from the underwriting discounts and offering expenses, as an increase to Additional Paid-In Capital.
 

Note 12. Contingencies

Legal proceedings

 
       Subsequent to September 30, 2021, the Company reached preliminary settlement on an employees related matter in the US. The financial statements for the third quarter include a provision in respect of this settlement.

The Company is a party to various legal proceedings from time to time, the outcome of which, in the opinion of management, will not have a significant effect on the financial position, profitability or cash flows of the Company.

     

 

18

 
2021-09-30 Includes $18 million and $14.2 million under long term deferred revenue in the Company's consolidated balance sheets as of September 30, 2021 and December 31, 2020, respectively. The goodwill was acquired as part of the RPS acquisition. See Note 3. The goodwill was acquired as part of the Origin acquisition. See Note 3. false --12-31 Q3 6-K 1 Holtzman Street P.O. Box 2496 Science Park Rehovot IL 76124 0001517396 001-35751 STRATASYS LTD. 0001517396 2021-01-01 2021-09-30 0001517396 2021-09-30 0001517396 2020-12-31 0001517396 us-gaap:ProductMember 2021-07-01 2021-09-30 0001517396 us-gaap:ProductMember 2020-07-01 2020-09-30 0001517396 us-gaap:ProductMember 2021-01-01 2021-09-30 0001517396 us-gaap:ProductMember 2020-01-01 2020-09-30 0001517396 us-gaap:ServiceMember 2021-07-01 2021-09-30 0001517396 us-gaap:ServiceMember 2020-07-01 2020-09-30 0001517396 us-gaap:ServiceMember 2021-01-01 2021-09-30 0001517396 us-gaap:ServiceMember 2020-01-01 2020-09-30 0001517396 2021-07-01 2021-09-30 0001517396 2020-07-01 2020-09-30 0001517396 2020-01-01 2020-09-30 0001517396 us-gaap:CommonStockMember 2020-12-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001517396 us-gaap:RetainedEarningsMember 2020-12-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001517396 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001517396 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001517396 2021-01-01 2021-03-31 0001517396 us-gaap:CommonStockMember 2021-03-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001517396 us-gaap:RetainedEarningsMember 2021-03-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001517396 2021-03-31 0001517396 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001517396 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001517396 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001517396 2021-04-01 2021-06-30 0001517396 us-gaap:CommonStockMember 2021-06-30 0001517396 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001517396 us-gaap:RetainedEarningsMember 2021-06-30 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001517396 2021-06-30 0001517396 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001517396 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001517396 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001517396 us-gaap:CommonStockMember 2021-09-30 0001517396 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001517396 us-gaap:RetainedEarningsMember 2021-09-30 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001517396 us-gaap:CommonStockMember 2019-12-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001517396 us-gaap:RetainedEarningsMember 2019-12-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001517396 2019-12-31 0001517396 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001517396 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001517396 2020-01-01 2020-03-31 0001517396 us-gaap:CommonStockMember 2020-03-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001517396 us-gaap:RetainedEarningsMember 2020-03-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001517396 2020-03-31 0001517396 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001517396 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001517396 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001517396 2020-04-01 2020-06-30 0001517396 us-gaap:CommonStockMember 2020-06-30 0001517396 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001517396 us-gaap:RetainedEarningsMember 2020-06-30 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001517396 2020-06-30 0001517396 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001517396 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001517396 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001517396 us-gaap:CommonStockMember 2020-09-30 0001517396 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001517396 us-gaap:RetainedEarningsMember 2020-09-30 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001517396 2020-09-30 0001517396 ssys:BusinessCombinationMember 2021-01-01 2021-09-30 0001517396 2020-12-01 2020-12-31 0001517396 ssys:XAARMember 2021-11-01 0001517396 2021-10-25 2021-11-01 0001517396 2021-02-01 2021-02-16 0001517396 us-gaap:ProductMember srt:AmericasMember 2021-07-01 2021-09-30 0001517396 us-gaap:ProductMember srt:AmericasMember 2020-07-01 2020-09-30 0001517396 us-gaap:ProductMember srt:AmericasMember 2021-01-01 2021-09-30 0001517396 us-gaap:ProductMember srt:AmericasMember 2020-01-01 2020-09-30 0001517396 us-gaap:ServiceMember srt:AmericasMember 2021-07-01 2021-09-30 0001517396 us-gaap:ServiceMember srt:AmericasMember 2020-07-01 2020-09-30 0001517396 us-gaap:ServiceMember srt:AmericasMember 2021-01-01 2021-09-30 0001517396 us-gaap:ServiceMember srt:AmericasMember 2020-01-01 2020-09-30 0001517396 srt:AmericasMember 2021-07-01 2021-09-30 0001517396 srt:AmericasMember 2020-07-01 2020-09-30 0001517396 srt:AmericasMember 2021-01-01 2021-09-30 0001517396 srt:AmericasMember 2020-01-01 2020-09-30 0001517396 us-gaap:ProductMember us-gaap:EMEAMember 2021-07-01 2021-09-30 0001517396 us-gaap:ProductMember us-gaap:EMEAMember 2020-07-01 2020-09-30 0001517396 us-gaap:ProductMember us-gaap:EMEAMember 2021-01-01 2021-09-30 0001517396 us-gaap:ProductMember us-gaap:EMEAMember 2020-01-01 2020-09-30 0001517396 us-gaap:ServiceMember us-gaap:EMEAMember 2021-07-01 2021-09-30 0001517396 us-gaap:ServiceMember us-gaap:EMEAMember 2020-07-01 2020-09-30 0001517396 us-gaap:ServiceMember us-gaap:EMEAMember 2021-01-01 2021-09-30 0001517396 us-gaap:ServiceMember us-gaap:EMEAMember 2020-01-01 2020-09-30 0001517396 us-gaap:EMEAMember 2021-07-01 2021-09-30 0001517396 us-gaap:EMEAMember 2020-07-01 2020-09-30 0001517396 us-gaap:EMEAMember 2021-01-01 2021-09-30 0001517396 us-gaap:EMEAMember 2020-01-01 2020-09-30 0001517396 us-gaap:ProductMember srt:AsiaPacificMember 2021-07-01 2021-09-30 0001517396 us-gaap:ProductMember srt:AsiaPacificMember 2020-07-01 2020-09-30 0001517396 us-gaap:ProductMember srt:AsiaPacificMember 2021-01-01 2021-09-30 0001517396 us-gaap:ProductMember srt:AsiaPacificMember 2020-01-01 2020-09-30 0001517396 us-gaap:ServiceMember srt:AsiaPacificMember 2021-07-01 2021-09-30 0001517396 us-gaap:ServiceMember srt:AsiaPacificMember 2020-07-01 2020-09-30 0001517396 us-gaap:ServiceMember srt:AsiaPacificMember 2021-01-01 2021-09-30 0001517396 us-gaap:ServiceMember srt:AsiaPacificMember 2020-01-01 2020-09-30 0001517396 srt:AsiaPacificMember 2021-07-01 2021-09-30 0001517396 srt:AsiaPacificMember 2020-07-01 2020-09-30 0001517396 srt:AsiaPacificMember 2021-01-01 2021-09-30 0001517396 srt:AsiaPacificMember 2020-01-01 2020-09-30 0001517396 us-gaap:ProductMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0001517396 us-gaap:ProductMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0001517396 us-gaap:ProductMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0001517396 us-gaap:ProductMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-09-30 0001517396 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0001517396 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0001517396 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0001517396 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-09-30 0001517396 us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0001517396 us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0001517396 us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0001517396 us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-09-30 0001517396 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0001517396 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember 2020-07-01 2020-09-30 0001517396 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-09-30 0001517396 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-09-30 0001517396 us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0001517396 us-gaap:TransferredOverTimeMember 2020-07-01 2020-09-30 0001517396 us-gaap:TransferredOverTimeMember 2021-01-01 2021-09-30 0001517396 us-gaap:TransferredOverTimeMember 2020-01-01 2020-09-30 0001517396 ssys:StratasysObjetReportingUnitMember 2021-01-01 2021-09-30 0001517396 srt:MinimumMember ssys:StratasysObjetReportingUnitMember 2021-01-01 2021-09-30 0001517396 srt:MaximumMember ssys:StratasysObjetReportingUnitMember 2021-01-01 2021-09-30 0001517396 us-gaap:GoodwillMember 2020-12-31 0001517396 us-gaap:GoodwillMember 2021-01-01 2021-09-30 0001517396 us-gaap:GoodwillMember 2021-09-30 0001517396 us-gaap:DevelopedTechnologyRightsMember 2021-09-30 0001517396 us-gaap:DevelopedTechnologyRightsMember 2020-12-31 0001517396 us-gaap:PatentsMember 2021-09-30 0001517396 us-gaap:PatentsMember 2020-12-31 0001517396 us-gaap:TrademarksAndTradeNamesMember 2021-09-30 0001517396 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0001517396 us-gaap:CustomerRelationshipsMember 2021-09-30 0001517396 us-gaap:CustomerRelationshipsMember 2020-12-31 0001517396 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-09-30 0001517396 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-12-31 0001517396 us-gaap:OtherIntangibleAssetsMember 2021-09-30 0001517396 us-gaap:OtherIntangibleAssetsMember 2020-12-31 0001517396 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001517396 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001517396 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001517396 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:MeasurementInputConversionPriceMember 2020-09-30 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember ssys:MeasurementInputConversionOfPriceMember 2020-09-30 0001517396 us-gaap:NondesignatedMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2021-09-30 0001517396 us-gaap:NondesignatedMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2020-12-31 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2021-09-30 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2020-12-31 0001517396 us-gaap:NondesignatedMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember 2021-09-30 0001517396 us-gaap:NondesignatedMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember 2020-12-31 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember 2021-09-30 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember 2020-12-31 0001517396 us-gaap:EmployeeStockOptionMember 2021-09-30 0001517396 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001517396 ssys:RestrictedAndPhantomShareUnitsMember 2021-09-30 0001517396 ssys:RestrictedAndPhantomShareUnitsMember 2021-01-01 2021-09-30 0001517396 ssys:OrdinarySharesMember 2021-01-01 2021-03-31 0001517396 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0001517396 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0001517396 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0001517396 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0001517396 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001517396 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001517396 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001517396 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001517396 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0001517396 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0001517396 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0001517396 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0001517396 ssys:StockbasedCompensationPlansMember 2021-07-01 2021-09-30 0001517396 ssys:StockbasedCompensationPlansMember 2020-07-01 2020-09-30 0001517396 ssys:StockbasedCompensationPlansMember 2021-01-01 2021-09-30 0001517396 ssys:StockbasedCompensationPlansMember 2020-01-01 2020-09-30 0001517396 ssys:RestrictedAndPhantomShareUnitsMember 2020-12-31 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-09-30 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 iso4217:USD iso4217:ILS xbrli:shares xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS iso4217:EUR